Skip to main content
. 2014 Jan 17;53(5):890–899. doi: 10.1093/rheumatology/ket475

Table 4.

Therapeutic agents used for the treatment of rheumatoid vasculitis and outcomes at the Mayo Clinic (Rochester, MN, USA), 2000–10

Treatment
    Corticosteroids (oral and/or i.v.) 83/86 (99)
        Orala 69/83 (83)
        i.v. pulse therapy 2/83 (2)
        Oral and i.v. pulse 12/83 (14)
    CYC (oral or i.v.) 24 (29)
        Oral 14 (16)
        i.v. 9 (10)
        Oral and i.v. 1 (1)
    Other DMARDs 46 (55)
        HCQ 7 patients
        MTX 26 patients
        AZA 12 patients
        MMF 3 patients
        Minocycline 1 patient
    Biologic response modifiers 21/74b (28)
        Anti-TNF agents 12 patients
        Rituximab 6 patients
        Abatacept 1 patient
        Anakinra 2 patients
Outcomes
    Follow-up, median (IQR), months 16 (2.4–59)
    Response to treatment (6 months after treatment initiation)
        Complete response 33 (38)
        Partial response 45 (52)
        No response 8 (10)
    Relapse at 5 years (similar or different clinical presentation) 36%
    Mortality rate (at 5 years) 26%

Values are n (%) unless indicated otherwise. aThe median starting dose of oral steroid was a prednisone equivalent of 40 mg (IQR 27.5–60). bData missing on 12 patients.